Broad Antibody Mediated Cross-Neutralization and Preclinical Immunogenicity of New Codon-Optimized HIV-1 Clade CRF02_AG and G Primary Isolates 英文参考文献.docVIP

下载本文档

3
0
约4.02万字
约 8页
2017-05-11 发布于上海
举报
版权申诉

Broad Antibody Mediated Cross-Neutralization and Preclinical Immunogenicity of New Codon-Optimized HIV-1 Clade CRF02_AG and G Primary Isolates 英文参考文献.doc

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

Broad Antibody Mediated Cross-Neutralization and Preclinical Immunogenicity of New Codon-Optimized HIV-1 Clade CRF02_AG and G Primary Isolates 英文参考文献

BroadAntibodyMediatedCross-Neutralizationand PreclinicalImmunogenicityofNewCodon-Optimized HIV-1CladeCRF02_AGandGPrimaryIsolates SimonM.Agwale1,2*,JosephC.Forbi1,2,FrankNotka3,TerriWrin4,JensWild5,RalfWagner3,5 ,Hans Wolf5 1ClinicalVirologyLaboratory,InnovativeBiotech,Keffi/Abuja,Nigeria,2FrederickInnovativeTechnologyCenter,InnovativeBiotech,Frederick,Maryland,UnitedStatesof America,3GeneArtAG,Regensburg, Germany,4Monogram Biosciences Inc., SouthSan Francisco, California, United States ofAmerica, 5Molecular Microbiology and GeneTherapyUnit,InstituteforMedicalMicrobiologyandHygiene,UniversityofRegensburg,Regensburg,Germany Abstract Creation of an effective vaccine for HIV has been an elusive goal of the scientific community for almost 30 years. Neutralizingantibodiesareassumedtobepivotaltothesuccessofaprophylacticvaccinebutpreviousattemptstomake animmunogencapableofgeneratingneutralizingantibodiestoprimary‘‘streetstrain’’isolateshaveresultedinresponses ofverylimitedbreadthandpotency.Theobjectiveofthestudywastodeterminethebreadthandstrengthofneutralizing antibodiesagainstautologousandheterologousprimaryisolatesinacohortofHIV-1infectedNigeriansandtocharacterize envelopes from subjects with particularly broad or strong immune responses for possible use as vaccine candidates in regionspredominatedbyHIV-1CRF02_AGandGsubtypes.EnvelopevectorsfromapanelofprimaryNigerianisolateswere constructed and tested with plasma/sera from the same cohort using the PhenoSense HIV neutralizing antibody assay (MonogramBiosciencesInc,USA)toassessthebreadthandpotencyofneutralizingantibodies.Theimmediategoalofthis studywasrealizedbytherecognitionofthreebroadlycross-neutralizingsera:(NG2-cladeCRF02_AG,NG3-cladeCRF02_AG and NG9- clade G). Based on these findings, envelope gp140 sequences from NG2 and NG9, complemented with agag sequence(CladeG)andconsensustat(CRF02_AGandG)antigenshavebeencodon-optimized,synthesized,clonedand evaluatedinBALB/cmice.TheintramuscularadministrationoftheseplasmidD